Laura Rodgers, NP
Acute Care · Center, TXNPI 1043659717
Payments from drug & device makers
Across 301 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$701
- AstraZeneca$682
- Boehringer Ingelheim$625
- Lilly USA, LLC$566
- Novo Nordisk$532
- Pfizer$523
- plus $1K from 21 others
What the payments were for
- Food & beverage$4,81495%
- Education$2425%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $701 |
| AstraZeneca | 36 | $682 |
| Boehringer Ingelheim | 39 | $625 |
| Lilly USA, LLC | 43 | $566 |
| Novo Nordisk | 33 | $532 |
| Pfizer | 30 | $523 |
| Bayer | 15 | $263 |
| Astellas Pharma US Inc | 5 | $236 |
| Amgen | 14 | $199 |
| Otsuka America Pharmaceutical, Inc. | 8 | $173 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $107 |
| GSK | 6 | $88 |
| Idorsia Pharmaceuticals US Inc | 5 | $68 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $51 |
| Antares Pharma, Inc. | 2 | $43 |
| Merck | 2 | $31 |
| Dexcom, Inc. | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Enterra Medical, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Alkermes, Inc. | 1 | $15 |
| Almatica Pharma LLC | 1 | $13 |
| Optinose US, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $4 |
How this compares
$5,056 in reported general payments places this provider in the 90th percentile of 2,323 acute care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 58 | $74,964 |
| MounjaroTirzepatide | 37 | $47,001 |
| EliquisApixaban | 34 | $41,192 |
| JardianceEmpagliflozin | 19 | $27,912 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $20,923 |
| JanuviaSitagliptin Phosphate | 16 | $15,521 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $14,757 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $13,370 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 11 | $12,977 |
| XareltoRivaroxaban | 13 | $8,909 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $7,668 |
| MyrbetriqMirabegron | 14 | $6,640 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $6,511 |
| Levothyroxine Sodium | 254 | $3,075 |
| Omeprazole | 183 | $2,795 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $532 | $74,96458 claims |
| Lilly USA, LLCMounjaro | $566 | $47,00137 claims |
| PfizerEliquis, Paxlovid | $523 | $42,62148 claims |
| Boehringer IngelheimJardiance, Trijardy Xr | $625 | $40,88930 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $88 | $28,59138 claims |
| MerckJanuvia | $31 | $15,52116 claims |
| Astellas Pharma US IncMyrbetriq | $236 | $6,64014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,323 acute care providers in Texas.
Other acute care in Center
- Jennifer PilotteDallas$232K
- Christie MorrisonSan Antonio$225K
- Amanda BradleyDallas$85K
- Laura WilsonEl Paso$32K
- Kim HuynhCypress$29K
- Martha LibertyDallas$28K
- Afton DickersonHouston$27K
- Eleanor WeltgeHouston$25K
- Leslie GutierrezHouston$25K
- Bahia ElkamandSugar Land$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.